Category Archives: Global News Feed

PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.

Read more:
Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the...

Scientific Journal Article follows notable IP updates, including publication of key PCT Patent Application, presentation at International Society for Research into Psychedelics Conference Scientific Journal Article follows notable IP updates, including publication of key PCT Patent Application, presentation at International Society for Research into Psychedelics Conference

More:
PharmAla Data to be Published in ACS Chemical Neuroscience

The Company’s Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM’s Digital Assay Reader

Read the rest here:
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation

Repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection, and a pharmacodynamic profile greater than injection

See more here:
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge...

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference –

Read more from the original source:
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024.

Continued here:
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2023 financial results will be released on Tuesday, February 27, 2024 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Visit link:
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00...

BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.

Original post:
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET.

Go here to read the rest:
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

Innovations and know-how in exosome production suited for many clinical applications Innovations and know-how in exosome production suited for many clinical applications

Go here to read the rest:
NurExone’s Intellectual Property Portfolio Expands